2017
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies
Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular side effectsHematologic malignanciesSide effectsUnique side effect profileCardiovascular adverse eventsSide effect profileLong-term administrationNon-Hodgkin lymphomaChronic myeloid leukemiaTyrosine kinase inhibitorsYears of ageOrgan-specific toxicityAdverse eventsFace of treatmentTargeted agentsEffect profilePatient populationCardiovascular toxicityMyeloid leukemiaNew agentsPreemptive managementMalignancyPrior exposureKinase inhibitorsProteasome inhibitors
2016
Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas
Sethi TK, Keedy VL. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas. Current Treatment Options In Oncology 2016, 17: 11. PMID: 26931561, DOI: 10.1007/s11864-015-0382-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTyrosine kinase inhibitorsTreatment optionsEfficacy of TKIsMulti-targeted tyrosine kinase inhibitorAlveolar soft part sarcomaKinase inhibitorsNon-GIST sarcomasSpectrum of sarcomasFirst-line treatmentEfficacy of imatinibSoft tissue sarcomasImportant clinical questionsPoor response ratesSoft part sarcomaTarget-specific agentsDermatofibrosarcoma protruberansUnresectable diseaseAdvanced sarcomasRECIST criteriaBone sarcomasClinical efficacyTissue sarcomasRare tumorPreclinical dataChemotherapeutic options